Halozyme Therapeutics (HALO) FY2016 results: revenue $147 million, up 8.6% on the year
Halozyme Therapeutics, Inc. (HALO) reported revenue of $147 million for fiscal 2016, the year ended 31 December 2016, up 8.6% on the year before. Net income was -$103 million, and diluted earnings per share $-0.81. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2017.
Revenue
$147 million
+8.6% on the year
FY2009FY2016
Operating margin
-56.7%
-20.3% a year earlier
FY2009FY2016
Net income
-$103 million
FY2009FY2016
Diluted EPS
-$0.81
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
147
135
75.3
+8.6%
Cost of revenue
33.2
29.2
22.7
+13.5%
Gross profit
113
106
52.6
+7.3%
Gross margin
77.4%
78.3%
69.8%
Research and development
151
93.2
79.7
+61.8%
Selling, general and administrative
45.9
40.0
35.9
+14.6%
Operating income
-83.2
-27.5
-63.0
Operating margin
-56.7%
-20.3%
-83.7%
Interest expense
20.0
5.2
5.6
+284.1%
Pre-tax income
-102
-32.2
-68.4
Income tax
1.2
0.0
0.0
Net income
-103
-32.2
-68.4
Net margin
-70.2%
-23.9%
-90.8%
Diluted EPS
-$0.81
-$0.25
-$0.56
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
-50.4
-37.1
-47.5
Capital expenditure
3.1
2.4
1.4
+32.9%
Free cash flow
-53.5
-39.4
-48.9
Free cash flow margin
-36.5%
-29.2%
-64.9%
Cash from investing
-76.8
5.9
-33.0
Cash from financing
151
13.1
115
+1,050.0%
Depreciation and amortisation
2.4
1.7
1.8
+43.7%
Share-based compensation
25.6
20.8
15.3
+22.8%
Diluted shares, weighted
128m
127m
n/a
+1.0%
Shares outstanding at period end
130m
128m
126m
+1.1%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
-32.5
43.0
41.4
Debt
217
49.8
49.9
+334.7%
Other liabilities
77.4
89.0
74.8
-13.0%
Total liabilities and equity
262
182
166
+43.9%
Fixed assets
4.3
3.9
3.0
+8.1%
Investments
138
65.0
74.2
+112.5%
Cash and equivalents
66.8
43.3
61.4
+54.2%
Receivables
15.7
32.4
9.1
-51.6%
Inventory
14.6
9.5
6.4
+54.1%
Other assets
22.0
27.6
11.8
-20.4%
Total assets
262
182
166
+43.9%
10-K for the year ended 31 December 2016, filed 28 February 2017: the filing.